Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

SB 883, known as the "Right to Treat Act," allows Texas physicians to prescribe FDA-approved prescription drugs for off-label use (meaning a purpose not approved by the FDA) in treating patients diagnosed with or exposed to COVID-19, without state interference. The bill prohibits state officials from restricting such prescriptions and prevents the Texas Medical Board from taking disciplinary action against a physician’s license based solely on off-label prescribing for COVID-19, provided the treatment meets the medical standard of care. It also clarifies that the law does not create legal liability for drug manufacturers or physicians if harm occurs from off-label use in treating COVID-19. The bill directly affects physicians, patients with COVID-19, and state licensing authorities.